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ability to access these trials usually depends on their clinician’s
involvement. Obtaining information about trials is often very
challenging for patients. The main issue is time, which cancer
patients lack.
HTAs sometimes present barriers to patient access. Different
countries take different approaches to HTAs and sometimes
arrive at different conclusions about a given treatment. The pro-
cess delays patient access. If a product is approved, is its use guar-
anteed or merely a recommendation? If it is not approved, the
regulatory agency needs to be transparent about the reason. Ben-
efits include more than just survival endpoints; quality of life and
symptom control are also very important. Extending life, if only
by a few months, can be critical to some patients. Having a life-
threatening disease also affects the degree to which patients
are willing to take risks. Therefore, measuring cost effectiveness
is complex, and priorities might be very different near the end
of a patient’s life.
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In principle, reimbursement for oncology therapeutics is extre-
mely good, especially in the United States. Medicare is required
to pay for indicated and compendia-listed off-label uses regard-
less of price. There is currently no system in place to measure
cost–benefit and impact of a new therapy. The trend in pricing
of new therapies has been steadily upward with cost in the range
of US $55,000 to $100,000 currently being obtained. Oncology drug
pricing has recently come under scrutiny, and if prices go too
high, the legislature would probably consider instituting some
limits. Co-payments are becoming a concern, however; Medicare
patients have to pay 20% out of their own pockets – a significant
sum considering the annual cost of some treatments. Neverthe-
less, secondary coverage is available, and many drug companies
have programs to help patients.
In the United States, payers and oncologists consider cost to
be of lower priority than clinical measures (Fig. 1). Sixteen payer
plans do not consider the cost of cancer treatment in their cover-
age decisions at all, largely because they follow Medicare cover-
age which is required to pay for approved oncology
therapeutics. However, oncologists’ treatment choices can be
affected by their perception of patients’ ability to pay.1
Favrille is the manufacturer of a personalised active immuno-
therapy product for B-cell non-Hodgkin’s lymphoma known as
mitumprotimut-T (FavId, Id-KLH, Idiotype vaccine) which is
given together with granulocyte-macrophage colony-stimulating
factor (Leukine, sargramostim, GM-CSF). It is custom-prepared
from individual patients’ tumour cells. Currently in phase III tri-
als, this immunotherapy appears to meet the criteria of what
the Centres for Medicare and Medicaid Services (CMS) would con-
sider an oncology therapeutic.
There are four main issues of concern for the reimbursement
of active immunotherapies in the United States: (1) Coverage
under Medicare Part B (physician administered) for a non-intrave-
nously administered (i.e sub-cutaneous or intra-Muscular) prod-
uct will require justification for the treatment to not be
considered self-administered (2) Co-administration of GM-CSF
(Leukine, sargramostim) will require coverage for use with the
active immunotherapy (3) 3rd party payer misconceptions that
this treatment should be covered in the same manner as prophy-
lactic vaccines, which are generally sub-optimal in the US, and
needs to be pro-actively addressed. (4) Coverage of a processing
fee could be problematic as this is usually associated with diag-
nostic procedures not therapeutics.
In the European Union, drug costs continue to be an issue
despite strict protocols for the use of expensive oncology prod-
ucts. Centralised procedures exist for the assessment of new
products and their cost-effectiveness, the most well known being
NICE in the United Kingdom. Furthermore, the majority of cancer
care in Europe is delivered through specialised, tertiary care cen-
tres or hospitals. These centres for the most part have fixed
annual budgets and treatment decisions are guided by set proto-
cols. An expensive new oncology therapeutic, such as an active
immunotherapy, must have sufficient supportive clinical and
pharmacoeconomic evidence to change these protocols and com-
pete for the limited financial resources of the institution. Glee-
vec is an example of an expensive, novel, oncology therapeutic
that has achieved success in Europe despite these hurdles – sales
in Europe as a percentage of global sales exceed those of the US.
In summary, reimbursement is not a significant concern if the
following criteria are met:
• Significant improvements in meaningful clinical endpoints are
demonstrated (e.g. time to disease progression, overall sur-
vival in randomised studies).
• Payment and reimbursement should be on a final per-product-
vial basis; avoid processing charges, which can complicate the
reimbursement process.
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• The price of the product should reflect the improvement in
patient outcomes. About $55,000 per annum for a novel
therapy is the current US benchmark, and Euro 55.000
per quality-adjusted life year (or progression-free year) is
probably a reasonable assumption about the practical price
limit in Europe. In the United States, patient assistance
programs and co-pay assistance can help patients obtain
reimbursement and minimise the possibility that co-pay-
ments would limit use. For Europe, a pharmacoeconomic
study is needed.
Increasing cost containment is already taking place in both
Europe and the United States.
When considering clinical trial design, appropriately sized
patient subgroups with a higher likelihood of a treatment benefit
should be prospectively defined to increase the likelihood of a
positive outcome of the study. Furthermore, clinical end-points,
the efficacy improvement required in the treatment arm and
the control arm selected should all be considered with pharmaco-
economic and reimbursement relevance in mind. Ideally, future
pivotal trials should include a built-in pharmacoeconomic
assessment.
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Pancreatic cancer is the fourth leading cause of cancer death and
has a median overall survival of 6 months. The median progres-
sion-free survival time (PFS) is 3 months. One-year overall sur-
vival is about 19%, and the 5-year overall survival is about 2%.
Gemcitabine used to be the only approved agent for treating the
disease in the European Union.
Both epidermal growth factor receptor (EGFR) and Her-2/neu
are overexpressed, activated, or both in most pancreatic cancers1
In vitro data and animal models support EGFR as a potentially
promising agent in pancreatic cancer,2 providing a rationale for
use of erlotinib (Tarceva), an orally available, reversible tyrosine
kinase inhibitor of EGFR.
A phase III trial of erlotinib plus gemcitabine compared with
gemcitabine monotherapy in patients with advanced pancreatic
cancer3 revealed no significant difference in the sum of complete
responses plus partial responses, but a difference was detected
when stable disease was also considered. A comparison of overall
survival in the two study arms revealed little difference, but PFS
was slightly but significantly improved among patients receiving
the combination therapy. The advantage in PFS became apparent
at 3–4 months of treatment, after which the curves for both study
arms were parallel (Fig. 1).
In sum, the combination of erlotinib plus gemcitabine
improved overall survival by about 12 days by delaying progres-
sion of disease. Side effects such as rash and diarrhoea were more
common in the combination-therapy group, but grade 3 or 4 tox-
icities were rare in both groups. Interestingly, patients who
received combination therapy and experienced skin toxicity
exceeding grade1 in severity had better overall and 1-year sur-
vival.3 Exploratory subpopulation analyses suggest that patients
in generally good condition or with distant metastases may
derive enhanced survival benefit.
Fig. 1 – Cost is of lower priority compared with clinical measures for oncologists and payers (chart on left) when it comes to
choosing therapies. The right-hand figure shows relative importance of various factors considered by payers making decisions
about treatment coverage.2
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